Ascletis Pharma to Host Obesity Portfolio Webinar on April 2, 2025USA - EnglishAPAC - Traditional ChineseAPAC - English

Ascletis Pharma to Host Obesity Portfolio Webinar on April 2, 2025 USA - English APAC - Traditional Chinese APAC - English News provided by Ascletis Pharma Inc. Mar 20, 2025, 07:00 ET Share this article Share to X Share this article Share to X HONG KONG , March 20, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672, "Ascletis") announces it will host an Obesity Portfolio Webinar on April 2, 2025 , from 9:00 a.m. – 10:30 a.m. ET . The event will include a detailed discussion on Ascletis' obesity portfolio including exciting data about its potential best-in-class clinical stage GLP-1R biased small molecule agonist, ASC30, for both once daily oral tablet and once monthly subcutaneous injection administration. Jinzi Jason Wu , Ph.D., Founder, Chairman & CEO of Ascletis, and John Gargiulo , MBA, Chief Business Officer of Ascletis, will host Q&A immediately following the presentation. Presentation Date: Wednesday, April 2, 2025 Time: 9:00 a.m. – 10:30 a.m. Eastern Time Registration: To access and attend the virtual event, please register HERE . An archived replay of the webcast will be available at the same link HERE for 30 days following the event. If you have any questions, please contact [email protected] . About Ascletis Pharma Inc. Ascletis is an innovative R&D driven biotech listed on the Hong Kong Stock Exchange (1672.HK), covering the entire value chain from discovery and development to GMP manufacturing. Led by a management team with deep expertise and a proven track record, Ascletis is focused on two therapeutic areas with unmet medical needs from a global perspective: metabolic diseases and viral diseases. Ascletis has multiple clinical stage drug candidates in its R&D pipeline. For more information, please visit www.ascletis.com . Contact： Peter Vozzo ICR Healthcare 443-231-0505 (U.S.) [email protected] Ascletis Pharma Inc. PR and IR teams +86-181-0650-9129 ( China ) [email protected] [email protected] SOURCE Ascletis Pharma Inc. 21 % more press release views with Request a Demo × Modal title